Donate For Public and Patients Store Search

S020 - Dermatologic Surgery: Cosmetic Tips and Pearls

Saturday, March 2; 9:00 AM - 12:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Evaluate patients for the best cosmetic treatments.
  • Choose the most appropriate treatment for each patient.

Description

Cosmetic tips and pearls will be presented to enhance treatment options for the best cosmetic results. Topics covered will include surgery, lasers and other machines, fillers, botulinum toxins, peels etc. New techniques and pearls will be presented to make patient treatments easier.

Disclosures

  • Bertucci, Vince, MD: Allergan, Inc – C(Fees); Allergan, Inc. – A(Fees), I(Fees), SP(H); Croma-Pharma GmbH Austria – A(NC); Galderma Canada, Inc – A(Fees), SP(H); Galderma Laboratories, L.P. – A(Fees); Galderma USA – I(Fees); La Roche-Posay Laboratorie Pharmaceutique – A(Fees), SP(Fees); Merz Aesthetics – A(Fees), C(Fees), I(Fees); Revance Therapeutics, Inc. – C(Fees), I(Fees), SP(Fees); TEOXANE Laboratories – A(OB); Valeant Pharmaceuticals International – C(Fees);
  • Fabi, Sabrina G., MD: Allergan, Inc – I(Grants/Research Funding), Speaker/Faculty Education(H); Bausch Health – C(H), I(Grants/Research Funding); Croma-Pharma GmbH Austria – I(Grants/Research Funding); Endo International plc – C(H), I(Grants/Research Funding); Galderma Laboratories, LP – SP(H); Merz Aesthetics – I(Grants/Research Funding), Speaker/Faculty Education(H); Revance Therapeutics, Inc. – A(H), C(H), I(Grants/Research Funding); Roche Laboratories – Speaker/Faculty Education(H); SkinCeuticals LLC – SP(H);
  • Geronemus, Roy G., MD: Allergan, Inc – I(Grants/Research Funding); Allergan, Inc. – A(Grants/Research Funding); ArchiMedus – I(Grants/Research Funding); Candela Corporation – A(Grants/Research Funding), I(Grants/Research Funding); Cearna, Inc – A(Grants/Research Funding); Cynosure, Inc – A(Grants/Research Funding), I(Grants/Research Funding); Cytrellis Biosystems, Inc – A(Grants/Research Funding), I(ST), SH(ST); Endo Pharmaceuticals – I(Grants/Research Funding); Kerastem – I(Grants/Research Funding); Lutronic – A(Grants/Research Funding), I(Grants/Research Funding); Merz Aesthetics – I(Grants/Research Funding); Miramar Labs – I(Grants/Research Funding); New York Stem Cell Foundation – I(Grants/Research Funding); Revance Therapeutics, Inc. – I(Grants/Research Funding); Sciton Inc. – I(Grants/Research Funding); Sienna Biopharmaceuticals – I(Grants/Research Funding); Syneron Candela – A(Grants/Research Funding), I(Grants/Research Funding);
  • Glogau, Richard Gordon, MD: Gerson Lehrman Group – C(Fees); Revance Therapeutics, Inc. – C(OB), I(OB);
  • Landau, Marina, MD: Almirall – A(H); Galderma USA – SP(H); Ipsen – A(H); Merz Aesthetics – A(H);
  • Mariwalla, Kavita, MD: Aclaris Therapeutics Inc. – C(Fees); Galderma Argentina, S.A. – SP(Fees); Revance Therapeutics, Inc. – I(Grants/Research Funding); Skinfix, Inc. – C(Fees);
  • Matarasso, Seth L., MD: no financial relationships exist with commercial interests.
  • Monheit, Gary D., MD: Allergan, Inc. – C(H), I(Grants/Research Funding); Croma-Pharma GmbH Austria – I(Grants/Research Funding); Evolus, Inc. – I(Grants/Research Funding); Galderma Laboratories, L.P. – C(H), I(Grants/Research Funding); Merz Pharmaceuticals, LLC – C(H); Revance Therapeutics, Inc. – C(H), I(Grants/Research Funding); Sienna Biopharmaceuticals – I(Grants/Research Funding); Suneva Medical, Inc. – C(NC), I(Grants/Research Funding); TEOXANE Laboratories – I(Grants/Research Funding);
  • Narins, Rhoda S., MD: Allergan, Inc. – C(H); Galderma USA – I(Grants/Research Funding); Merz Aesthetics – C(H); Revance Therapeutics, Inc. – A(H); Suneva Medical, Inc. – I(Grants/Research Funding);
  • Ozog, David M., MD: Biofrontera AG – I(Grants/Research Funding), SH(NC); Galderma USA – I(Grants/Research Funding); miRagen Therapeutics, Inc. – I(Grants/Research Funding);
  • Shamban, Ava T., MD: Allergan, Inc – I(Grants/Research Funding), SP(H); Endo International plc – I(Grants/Research Funding); Merz Aesthetics – I(Grants/Research Funding), SP(H); Revance Therapeutics, Inc. – C(H), I(Grants/Research Funding); Sienna Biopharmaceuticals – I(Grants/Research Funding); TEOXANE Laboratories – I(Grants/Research Funding);
  • Solish, Nowell J., MD: Allergan, Inc – A(H); Allergan, Inc. – SP(H); Galderma USA – SP(H); International hyperhidrosis society – B(H); Revance Therapeutics, Inc. – A(H);
  • Tanzi, Elizabeth, MD: Beiersdorf, Inc. – SP(H); Merz Aesthetics – C(OB); Neutrogena Corporation – Independent Contractor(Fees); Sciton Inc. – I(OB); Soliton – A(Fees); Solta Medical – I(OB); Ulthera – SP(H); Zalea, LLC – A(Fees); Zeltiq Aesthetics – A(Fees);
  • Waibel, Jill S., MD: Alma Lasers – SP(H); Aquavit Pharmaceuticals – I(SO); Candela Corporation – SP(H); Cutera, Inc. – I(Grants/Research Funding); Lumenis – I(H); Lutronics, Inc. – I(Grants/Research Funding); Michelson Diagnostics Ltd. – I(EQ); Regenx – C(Grants/Research Funding); Sciton Inc. – I(Grants/Research Funding); Sebacia, Inc. – I(Grants/Research Funding); Vivosight – I(Grants/Research Funding); Zeltiq Aesthetics – SP(H);
Event Details
  • Date
    Saturday, March 2
  • Time
    9:00 AM - 12:00 PM
  • Location
    Ballroom A
  • CME Credits
    3.00
  • Type
    Restricted
Directors/Co-Directors
  • Gary D. Monheit, MD, FAAD
  • Rhoda S. Narins, MD, FAAD
Speakers
  • Ava T. Shamban, MD, FAAD
  • David M. Ozog, MD, FAAD
  • Elizabeth Tanzi, MD, FAAD
  • Jill S. Waibel, MD, FAAD
  • Kavita Mariwalla, MD, FAAD
  • Marina Landau, MD
  • Nowell J. Solish, MD, FAAD
  • Richard Gordon Glogau, MD, FAAD - Handout
  • Roy G. Geronemus, MD, FAAD
  • Sabrina G. Fabi, MD, FAAD
  • Seth L. Matarasso, MD, FAAD
  • Vince Bertucci, MD, FAAD